PHILADELPHIA, Nov. 9, 2009 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) announced its financial results for the three months ended September 30, 2009. The net loss (including non-cash expenses) for the fiscal quarter was approximately $2,435,000 or $0.02 per share compared to a loss of approximately $3,415,000 or $0.05 per share for the same period in 2008. The decrease in loss was primarily due to 1) lower R&D expenses related to the preparation of the Ampligen(R) NDA and, 2) the effect of reducing G&A expenses pursuant to the cash conservation and cost reduction program implemented by Management in early 2009. The net loss for the nine months ended September 30, 2009 including non-cash expenses was $9,392,000 or $0.09 per share compared to a loss of $9,382,000 or $0.13 per share in 2008.
